PTC 440000

Your search result can be sorted in ascending/descending order by clicking on the column headings, with the exception of Review Status/Past Decision(s).
* Please click on the DIN/PIN hyperlink to look up for more details of any group coverage(s) which may apply to that particular drug product.

Products Found: 8

MFR

Review Status/
Past Decision(s)

02204606
ALPHA 1-PROTEINASE
PROLASTIN-C
1 G / VIAL
INJ 
N/A
N/A
VIAL
NO

NOT A BENEFIT *

ASFOTASE ALFA
STRENSIQ
18 MG / VIAL
INJ 
1358.6400
N/A
VIAL
NO

SPECIAL AUTHORIZATION

ASFOTASE ALFA
STRENSIQ
28 MG / VIAL
INJ 
2113.4400
N/A
VIAL
NO

SPECIAL AUTHORIZATION

ASFOTASE ALFA
STRENSIQ
40 MG / VIAL
INJ 
3019.2000
N/A
VIAL
NO

SPECIAL AUTHORIZATION

ASFOTASE ALFA
STRENSIQ
80 MG / VIAL
INJ 
6038.4000
N/A
VIAL
NO

SPECIAL AUTHORIZATION

02388316
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
XIAFLEX
0.9 MG / VIAL
INJ 
N/A
N/A
VIAL
NO

NOT A BENEFIT *

02427184
ELOSULFASE ALFA
VIMIZIM
5 MG / VIAL
INJ 
N/A
N/A
VIAL
NO

NOT A BENEFIT *

02425637
TALIGLUCERASE ALFA
ELELYSO
200 UNIT / VIAL
INJ 
N/A
N/A
VIAL
NO

NOT A BENEFIT *


To return to the printable Drug Benefit List and related publications, click here.

Last Updated: null

NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.